Suppression of cell invasiveness by periostin via TAB1/TAK1

International Journal of Oncology

Volumn 35, Issue 2, 2009, Pages 425-432

  Isono, Takahiro ^a   Kim, Chul Jang ^b   Ando, Yukihiro ^a,c   Sakurai, Hiroaki ^d   Okada, Yusaku ^a   Inoue, Hirokazu ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Kohka Public Hospital   (Japan)

^c NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Bladder cancer; Invasion; Periosotin; TAB1; TAK1

Indexed keywords

BINDING PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1 BINDING PROTEIN 1; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; MAP KINASE KINASE KINASE 7; MAP3K7IP1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; POSTN PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CELL STRAIN HEK293; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; METASTASIS POTENTIAL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; BLADDER TUMOR; CANCER INVASION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL ADHESION MOLECULES; CELL LINE, TUMOR; HUMANS; MAP KINASE KINASE KINASES; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 69449086063     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000355     Document Type: Article

References (30)

1. Horiuchi K, Amizuka N, Takeshita S, et al: Identification and characterization of a novel protein, periostin, with restricted expression to periostium and periodontal ligament and increased expression by transforming growth factor β. J Bone Miner Res 14: 1239-1249, 1999.
2. Takeshita S, Kikuno R, Tezuka K and Amann E: Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 294: 271-278, 1993.
3. Katsuragi N, Morishita R, Nakamura N, et al: Periostin as a novel factor responsible for ventricular dilation. Circulation 110: 1806-1813, 2004.
4. Wang D, Oparil S, Feng JA, et al: Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension 42: 88-95, 2003.
5. Kuhn B, del Monte F, Hajjar R, et al: Periostin induces proliferation of differentiated cardiomyocytes and prootes cardiac repair. Nat Med 13: 962-969, 2007.
6. Oka T, Xu J, Kaiser RA, et al: Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res 101: 313-321, 2007.
7. Wilde J, Yokozeki M, Terai K, Kudo A and Moriyama K: The divergent expression of periostin mRNA in the periodontal ligament during experimental tooth movement. Cell Tissue Res 312: 345-351, 2003.
8. Rios H, Koushik SV, Wang H, et al: Periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol 25: 11131-11144, 2005.
9. Kudo Y, Siriwardena BS, Hatano H, Ogawa I and Takata T: Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol 22: 1167-1174, 2007.
10. Bao S, Ouyang G, Bai X, et al: Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5: 329-339, 2004.
11. Shao R, Bao S, Bai X, et al: Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through upregulation of vascular endothelial growth factor 2 expression. Mol Cell Biol 24: 3992-4003, 2004.
12. Sasaki H, Lo KM, Chen LB, et al: Expression of periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers. Jpn J Cancer Res 92: 869-873, 2001.
13. Kudo Y, Ogawa I, Kitajima S, et al: Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res 66: 6928-6935, 2006.
14. Siriwardena BS, Kudo Y, Ogawa I, et al: Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. Br J Cancer 95: 1396-1403, 2006.
15. Baril P, Gangeswaran R, Mahon PC, et al: Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the β4 integrin and the PI3k pathway. Oncogene 26: 2082-2094, 2007.
16. Kim CJ, Yoshioka N, Tambe Y, et al: Periostin is down-regulated in high grade bladder cancer and suppresses in vitro cell invasiveness and in vivo metastasis of cancer cells. Int J Cancer 117: 51-58, 2005.
17. Shimagaki M and Kudo A: Impaired capsule formation of tumors in periostin-null mice. Biochem Biophys Res Commun 367: 736-742. 2008.
18. Kim CJ, Isono T, Tambe Y, et al: Role of alternative splicing of periostin in human bladder carcinogenesis. Int J Oncol 32: 161-169, 2008.
19. Gillan L, Matei D, Fishman DA, et al: Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res 62: 5358-5364, 2002.
20. Yoshioka N, Fuji S, Shimakage M, et al: Suppression of anchorage-independent growth of human cancer cell lines by the TRIF52/ Periostin/OSF-2 gene. Exp Cell Res 279: 91-99, 2002.
21. Sakurai H, Miyoshi H, Toriumi W and Sugita T: Functional interactions of transforming growth factor beta-activated kinase 1 with IkappaB kinase to stimulate NF-kappaB activation. J Biol Chem 274: 10641-10648, 1999.
22. Naviaux RK, Constanzi E, Haas M and Verma IM: The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 70: 5701-5705, 1996.
23. Singhirunnusorn P, Suzuki S, Kawasaki N, Saiki I and Sakurai H: Critical roles of threonine 187 phosphorylation in culture stress-induced rapid and transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J Biol Chem 280: 7359-7368, 2004.
24. Isono T, Tanaka T, Kageyama S and Yoshiki T: Structural diversity of cancer-related and non-cancer-related prostate-specific antigen. Clin Chem 48: 2187-2194, 2002.
25. Shibuya H, Yamaguchi K, Shirakabe K, et al: TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 272: 1179-1182, 1996.
26. Yamaguchi K, Shirakabe K, Shibuya H, et al: Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270: 2008-2011, 1995.
27. Sakurai H, Shigemori N, Hasegawa K and Sugita T: TGF-beta-activated kinase 1 stimulates NF-kappa B activation by an NF-kappa B-inducing kinase-independent mechanism. Biochem Biophys Res Commun 243: 545-549, 1998.
28. Neil JR and Schiemann WP: Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. Cancer Res 68: 1462-1470, 2008.
29. Wada T and Penninger JM: Mitogen-activated protein kinase in apoptosis regulation. Oncogene 23: 2838-2849, 2004.
30. Cheng PC, Cambell DG, Nabreda AR and Cohen P: Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J 22: 5793-5805, 2003.